v3.26.1
Consolidated Balance Sheets - USD ($)
Mar. 31, 2026
Dec. 31, 2025
Current assets:    
Cash and cash equivalents $ 745,482 $ 4,310,354
Unbilled receivable 420,345
Prepaid expenses and other current assets 1,263,058 2,514,319
Total current assets 2,008,540 7,245,018
Property and equipment, net 117,596 124,129
Other assets 41,667 83,332
Total assets 2,167,803 7,452,479
Current liabilities:    
Accounts payable 1,610,186 3,267,610
Accrued expenses and other liabilities 980,780 993,411
Notes payable and accrued interest 245,849 306,708
Total current liabilities 2,836,815 4,567,729
Total liabilities 2,836,815 4,567,729
Commitments and contingencies (Note 6)
Stockholders’ equity (deficit)    
Preferred stock, $0.0001 par value, 1,500,000 shares authorized at March 31, 2026 and December 31, 2025; 4,000 shares issued at March 31, 2026 and December 31, 2025; 1,405 and 3,305 shares outstanding at March 31, 2026 and December 31, 2025, respectively; $1,545,500 and $3,635,500 liquidation preference at March 31, 2026 and December 31, 2025, respectively
Common stock, $0.0001 par value, 250,000,000 shares authorized at March 31, 2026 and December 31, 2025; 9,277,825 and 4,574,983 shares issued at March 31, 2026 and December 31, 2025, respectively; 9,277,819 and 4,574,977 shares outstanding at March 31, 2026 and December 31, 2025, respectively 929 459
Additional paid-in capital 142,935,443 142,933,260
Accumulated deficit (143,276,414) (139,719,999)
Total Ensysce Biosciences, Inc. stockholders’ equity (deficit) (340,042) 3,213,720
Noncontrolling interests in stockholders’ equity (deficit) (328,970) (328,970)
Total stockholders’ equity (deficit) (669,012) 2,884,750
Total liabilities and stockholders’ equity (deficit) $ 2,167,803 $ 7,452,479

Source

PDF HTML
ZIP XBRL